The European Commission has approved Shanghai Junshi Biosciences' (HKG:1877) toripalimab for the treatment of two indications, a Tuesday bourse filing said.
The first indication comprises toripalimab in combination with cisplatin and gemcitabine to treat adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.
The second indication involves toripalimab in combination with cisplatin and paclitaxel for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Shares of the company were up over 3% on Wednesday's close.
Price (HKD): $11.50, Change: $+0.36, Percent Change: +3.23%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。